Tambocor
(flecainide)ApprovedSmall molecule
Flecainide is used to treat abnormal heart rhythms (arrhythmias) by helping the heart beat in a more regular pattern. It slows down electrical signals in the heart to prevent dangerous irregular heartbeats.[2] Tambocor is currently approved and in use across 11 indications[4].[1]
Tambocor is one of 138 small molecule programs targeting Arrhythmogenic right ventricular dysplasia. It is currently in Approved.
11
Indications
25
Total Trials
8
Active Trials
137
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
137 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Tambocor
AAlvogen Korea
Approved
Calquence
AstraZenecaPreclinical
Rituxan
RochePreclinical
Coumadin
AAbbott
Preclinical
Imbruvica
PPharmacyclics LLC.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atrial Fibrillation7 trials
Paroxysmal atrial fibrillation4 trials
Beta Blockers Plus Intravenous Flecainide for Paroxysmal Atrial Fibrillation: a Real-world Chios Registry (BETAFLEC-CHIOS)
Completed·—··NCT04991896·81 enrolled
Show 1 more trial
Cardiac Arrhythmia3 trials
9 more indications
Ventricular Tachycardia1 trial
Cardiomyopathy1 trial
Supraventricular tachycardia1 trial
Atrial Fibrillation (AF)1 trial
Patent foramen ovale1 trial
Unspecified1 trial
N-of-1 in ATS and MEPPC
Not yet recruiting·—·Phase 2·NCT06205550·10 enrolled
Regulatory
FDA Approval Timeline[5]
Aug 23, 1988
TAMBOCOR
NDA NDA018830
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tambocor drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for flecainide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Sodium Channel Protein Type V Alpha Subunit Blocker[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- AAlvogen Korea